MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$9,468K
Atm offering, net of
offering costs
$6,392K
Proceeds from anson
convertible note, net
$5,000K
Proceeds from liability
classified warrants
$3,087K
Proceeds from issuance of
insurance loan
$227K
Net cash provided by
financing activities
$23,276K
Canceled cashflow
$898K
Net increase
(decrease) in cash and cash...
$6,354K
Canceled cashflow
$16,922K
Repayment of insurance
note
$548K
Expense for debt
issuance costs due to fair...
$350K
Loss on convertible
note conversions
-$6,201K
Change in fair value of
warrant liabilities
$4,926K
Change in fair value of
convertible promissory...
$3,939K
Loss on debt
settlement
-$1,277K
Prepaid expense and
other assets
-$865K
Loss on issuance of
registered direct common...
-$730K
Common stock issued in
exchange for services
$601K
Accrued expense and
other liabilities
$501K
Expense for debt
issuance costs due to fair...
$350K
Stock-based compensation
$228K
Accounts payable
$113K
Amortization of operating
right of use assets
$73K
Depreciation and
amortization expense
$70K
Account receivable
-$48K
Provision (recovery) for
expected credit losses
$40K
Loss on equity method
investments
-$35K
Net cash used in
operating activities
-$14,112K
Net cash used in
investing activities
-$2,810K
Canceled cashflow
$19,997K
Net loss
-$28,622K
Business acquisition,
net of cash acquired
$2,378K
Cash used in
investments
$432K
Gain on exercise of
warrant liabilities
$5,369K
Operating lease
liabilities
-$118K
Back
Back
Cash Flow
source: myfinsight.com
NRX Pharmaceuticals, Inc. (NRXPW)
NRX Pharmaceuticals, Inc. (NRXPW)